More about
Olaparib
News
July 07, 2020
4 min watch
Save
Olaparib shows 1-year survival benefit in recurrent ovarian cancer, BRCA mutations
News
July 07, 2020
4 min watch
Save
Cediranib, olaparib combo not superior in ovarian cancer outside of germline mutations
News
June 24, 2020
3 min watch
Save
VIDEO: Olaparib yields ‘impressive’ results in metastatic breast cancer
News
June 15, 2020
2 min watch
Save
VIDEO: Olaparib may offer chemotherapy alternative
News
May 20, 2020
1 min read
Save
FDA approves Lynparza for prostate cancer subset
News
May 13, 2020
3 min read
Save
Maintenance olaparib extends OS among women with BRCA-mutated relapsed ovarian cancer
News
May 08, 2020
2 min read
Save
FDA expands Lynparza approval for gynecologic cancer
News
April 27, 2020
4 min read
Save
Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer

Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting.
News
March 12, 2020
1 min read
Save
Phase 3 trial in relapsed ovarian cancer misses primary endpoint
News
January 21, 2020
1 min read
Save